Are Insights leaders seeing real commercial value from AI adoption yet?
Day One Strategy’s second annual AI in Pharma State of Play report – Are Insights leaders seeing real commercial value from AI adoption yet? – addresses the challenges Pharma Insights teams are facing as AI adoption continues to mean real structural change and an ever increasing pressure to accelerate to informed decisions.
Drawing on 20 in-depth interviews with Marketing and Insights leaders at global pharma companies, the report identifies 4 key insights into where real value is emerging and what it will take to attain competitive advantage, with better quality data and improved AI governance ever at the centre.
AI access and AI adoption are two different things, and AI adoption remains patchy to say the least. Indeed, many companies are still working out how to turn AI into measurable commercial value.
This gap between AI vision and proof has led Day One Strategy to create a new segment to join Cautionary, Follower, Everyday Afficionado, and Changeseeker: the Constrained Change Seeker.
The fear behind pharma’s caution on AI is real and justified. In a regulated, high-stakes environment, the cost of a wrong answer can be huge. From simple productivity and workflow redesign to embedded agentic models, the report identifies 3 actions that can be taken to show clearer ROI, and explains what humans need to do next.
Download the report to access practical guidance to help your company move forward in its AI journey today.
About Day One Strategy
Day One Strategy is the intelligence partner to the world's leading healthcare brands. Founded in 2019 by Hannah Mann and Abigail Stuart, the insights and strategy agency combines industry experts with InsightBrain, its AI decision engine built for healthcare, to help brand teams act with confidence from early opportunity assessment through to performance tracking. Day One is trusted by 8 of the top 10 global pharma companies and has 60+ experts in London and New York.
